2018 Partnerships & Pipeline

Lilly is in the early stages of a growth period catalyzed by recently launched products. Our pipeline’s potential remains strong, with new medicines in development to treat a range of diseases. Here are two things we talked about at the 2018 J.P. Morgan Healthcare Conference and will continue to speak to this year:

  1. Launching With Excellence

    • We have launched nine new medicines since 2014 for patients with unmet needs – and we expect to launch 11 more by 2023.
    • Lilly is focused on launch excellence so that physicians understand our new medicines and patients have access to them.
  2. Accelerating Innovation and Replenishing Our Pipeline
    • Lilly’s “Next Generation” initiatives in research and development have reduced the time to bring medicines to patients by two years, aiming to cut that even more.
    • We continue to evaluate external innovation opportunities – through acquisitions, alliances, licensing and our growing venture capital portfolio. We expect to source one-third of our pipeline by way of partnerships.

JPMHC18 V2 Lilly.com-940

This year holds much promise for partnerships, and thus the future of our pipeline. And this goal remains: getting high-quality medicines to patients as fast as we can.

Collaborate With Us 

Tell us about your idea, technology or innovation and how we can work together to bring it to life.

Scientific Partnering
Clinical Development Pipeline
Dave Ricks on LinkedIn 

I'm glad to join the board of directors doing great things at Adobe. Click here to learn more.

David A. Ricks Chairman and CEO, Lilly

"We’re trying to change the frontiers of what’s possible in medicine. Our vision is to change patients’ expectations – to provide a new sense of hope for people suffering from some of the world’s most debilitating diseases."